2. Study characteristics of the diagnostic test accuracy analyses studies.
Study | MRI | Index biopsy | Reference standard | Target conditions | |||||
Study | Consecutive enrolment (study designa) | N of participants | Index test(s) | MRI‐scale; threshold | MRI‐TBx Technique/route | Technique | Median N cores (range) | Independence | ISUP grade (G) |
Abd‐Alazeez 2014 | No (retrospective) | 54 | MRI | 1‐5; ≥ 3 | Cognitive/transperineal | TTMB | 45 (21‐137) | No | G = 1 G ≥ 2 G ≥ 3 |
Ahmed 2017 | Yes (prospective) | 576 | MRI, SBx | 1‐5; ≥ 3 | NA/transrectal | TTMB | > 40b | Yes | G = 1 G ≥ 2 G ≥ 3 |
Dal Moro 2019 | Yes (prospective) | 123 | MRI, MRI‐TBx, MRI‐pathway | 1‐5; ≥ 3 | Cognitive/transrectal | TSBc | 24d | Yes | G = 1 G ≥ 2 G ≥ 3 |
Distler 2017 | Yes (prospective) | Bx‐naïve: 597 Prior‐negative Bx: 443 | MRI, MRI‐TBx, MRI‐pathway | 1‐5; ≥ 3 | Software/transperineal | TSBe | 24 (22‐25) | No | G ≥ 2 |
Grey 2015 | Yes (prospective) | Bx‐naïve: 83 Prior‐negative Bx: 103 | MRI | 1‐5; ≥ 3 | Cognitive/transperineal | TSBe | (24‐40) | No | G = 1 G ≥ 2 G ≥ 3 |
Hansen 2016a | Yes (prospective) | 295 | MRI, MRI‐TBx, MRI‐pathway | 1‐5; ≥ 3 | Software/transperineal | TSBe | (18‐24) | Unclear | G = 1 G ≥ 2 G ≥ 3 |
Hansen 2018 | Yes (prospective) | Centre 1: 163 Centre 3: 242 | MRI | 1‐5; ≥ 3 | Software, cognitive/transperineal | TSBe | 24 (22‐26f), 20 (20‐21f) | No | G = 1 G ≥ 2 G ≥ 3 |
Hansen 2017 | Unclear (prospective) | 287 | MRI, MRI‐TBx, MRI‐pathway | 1‐5; ≥ 3 | Software/transperineal | TSBe | 24 (24‐25) | Unclear | G ≥ 2 |
Kesch 2017 | Unclear (prospective) | Bx‐naïve: 95 Prior‐negative Bx: 51 | MRI, MRI‐TBx, MRI‐pathway | 1‐5; ≥ 3 | Software/transperineal | TSBg | 24 (23‐27f) | Yes | G = 1 G ≥ 2 G ≥ 3 |
Lawrence 2014 | No (retrospective) | 39 | MRI, MRI‐TBx, MRI‐pathway | 1‐4; ≥2 | Software/transperineal | TSBe | 24 (14‐34) | No | G = 1 G ≥ 2 |
Mortezavi 2018 | Yes (retrospective) | 163 86 | MRI, MRI‐TBx, MRI‐pathway | 1‐5; ≥ 3 | Software/Transrectal | TSB | 40 (30‐55) | No | G = 1 G ≥ 2 G ≥ 3 |
Muthuveloe 2016 | Unclear (retrospective) | 9 162 | MRI | 1‐5; ≥ 3 | NA | TSBh | 24 (24–28) | Unclear | G = 1 G ≥ 2 G ≥ 3 |
Pepe 2013 | Unclear (prospective) | 78 | MRI, MRI‐TBx, MRI‐pathway | 0‐1: ≥1 | Cognitive/transrectal | TSBh | 28 (26‐32) | No | G = 1 G ≥ 2 |
Thompson 2016 | Yes (prospective) | 344 | MRI | 1‐5; ≥ 3 | Software, cognitive/transperineal | TTMB | 30 | No | G = 1 G ≥ 2 G ≥ 3 |
Tsivian 2017 | Unclear (retrospective) | 33 | MRI | 1‐5; ≥ 3 | NA | TTMB | 55 (42‐63f) | Yes | G = 1 G ≥ 2 G ≥ 3 |
Nafie 2014 | Unclear (prospective) | 50 | SBx | NA | NA/transrectal | TSBh | 36 | Yes | G = 1 G ≥ 2 G ≥ 3 |
Nafie 2017 | Unclear (prospective) | 42 | SBx | NA | NA/transrectal | TSBh | 36 | Yes | G = 1 G ≥ 2 |
Ploussard 2014 | Yes (prospective) | 2753 | SBx | NA | NA/transrectal | TSBc | 21 | No | G = 1 G ≥ 2 |
Bx: biopsy; ISUP G : International Society of Urological Pathology grade; MRI: magnetic resonance imaging; MRI‐pathway: magnetic resonance imaging with or without magnetic resonance imaging‐targeted biopsy; MRI‐TBx: magnetic resonance imaging‐targeted biopsy; N: number; NA: not applicable; PI‐RADS v1, v2: Prostate Imaging Reporting Data System version 1 or 2; SBx: systematic biopsy; TSB: transperineal saturation biopsy; TTMB: transperineal template mapping biopsy |
aIncluded participants were part of the same study cohort (no randomised populations were included). bNot reported but estimated. cTransrectal. dMean value (as opposed to median). eGinsburg biopsies. fInterquartile range (as opposed to range). gTransperineal optimised prostate biopsy (TOP). hIn‐house transperineal saturation biopsy